Trials / Completed
CompletedNCT03261635
Ranibizumab Plus Indomethacin
Prospective Randomized Controlled Trial of Combination Ranibizumab and Indomethacin for Exudative Age-Related Macular Degeneration
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 58 (actual)
- Sponsor
- Università degli Studi di Brescia · Academic / Other
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate whether indomethacin eyedrops plus intravitreal ranibizumab (IVR) provides additional benefit over IVR monotherapy for treatment of choroidal neovascularization (CNV) in age-related macular degeneration.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ranibizumab Injection | patients received monthly 0.5 mg ranibizumab intravitreal injections for 3 months, after which monthly injections were administered pro re nata |
| DRUG | Indomethacin | patients self-administered one drop of indomethacin 0.5% eye drops three times a day for 12 months |
Timeline
- Start date
- 2016-01-07
- Primary completion
- 2016-12-07
- Completion
- 2017-07-25
- First posted
- 2017-08-25
- Last updated
- 2017-08-25
Source: ClinicalTrials.gov record NCT03261635. Inclusion in this directory is not an endorsement.